Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Govind Ballabh Pant Hospital.
Recruitment status was  Recruiting
Information provided by:
Govind Ballabh Pant Hospital Identifier:
First received: August 2, 2010
Last updated: August 4, 2010
Last verified: October 2009
To assess the effects of lactulose for the prevention of first episode of altered sensorium (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.

Condition Intervention Phase
Hepatic Encephalopathy
Drug: Lactulose
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose

Resource links provided by NLM:

Further study details as provided by Govind Ballabh Pant Hospital:

Primary Outcome Measures:
  • prevention of first episode of hepatic encephalopathy [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Side effects to lactulose and mortality [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Study Start Date: January 2008
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lactulose Drug: Lactulose
In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
Drug: Lactulose
lactulose will be used in 30-60ml/day

Detailed Description:
Development of hepatic encephalopathy in a patient with cirrhosis is associated with poor survival rate of 10-70% at one year depending upon hepatic and renal functions. Treating patients to prevent development of first episode of hepatic encephalopathy is classified as primary prophylaxis of hepatic encephalopathy and preventing recurrence of hepatic encephalopathy in patients who had previous episode of hepatic encephalopathy is secondary prophylaxis of hepatic encephalopathy

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cirrhotic patients(18-70yrs) who never had encephalopathy

Exclusion Criteria:

  • history of taking lactulose in the past 6 weeks
  • alcohol intake during the past 6 weeks
  • hepatocellular carcinoma
  • previous TIPS or shunt surgery
  • significant co morbid illness such as heart, respiratory, or renal failure
  • neurologic diseases such as alzheimer's disease, parkinson's disease and nonhepatic metabolic encephalopathies.
  • patients on psychoactive drugs such as antidepressants or sedatives
  • who restarted alcohol during follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01175538

Contact: Barjesh C Sharma, MD,DM 9718599203

G B Pant Hospital Recruiting
New Delhi, Delhi, India, 110002
Contact: Barjesh C Sharma, MD,DM    9718599203   
Contact: Praveen Sharma, MD,DM    9810365151   
Principal Investigator: Barjesh C Sharma, MD,DM         
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Principal Investigator: Barjesh C Sharma, MD,DM G B Pant Hospital New Delhi 110002
  More Information

Responsible Party: Prof Barjesh Chander Sharma, G B Pant Hospital Identifier: NCT01175538     History of Changes
Other Study ID Numbers: PS001 
Study First Received: August 2, 2010
Last Updated: August 4, 2010
Health Authority: India: Institutional Review Board

Keywords provided by Govind Ballabh Pant Hospital:
Hepatic encephalopathy

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Brain Diseases, Metabolic
Central Nervous System Diseases
Digestive System Diseases
Hepatic Insufficiency
Liver Diseases
Liver Failure
Metabolic Diseases
Nervous System Diseases
Gastrointestinal Agents processed this record on May 26, 2016